Oh what might have been (and still an outside chance):
https://www.fiercepharma.com/pharma/jjs-car-t-partner-legend-biotech-reportedly-receives-buyout-offer
(J&J partnered with Legend in its genetically modified autologous T cell immunotherapy treatment for myeloma patients - with obvious reference to the research collaboration in ATI with J&J, which we understand is being shopped around in the US at last disclosure)
I missed a report on autologous MSC stem cells in the treatment of Achilles tendinopathy:
https://www.nature.com/articles/s41598-024-61399-3
I won't patronise OCC investors as to why tenocytes are so more obviously the more efficacious choice in tendinopathies - its well covered above for those who don't know. Oh ATI, wherefore art thou at? Lets hope we get a little more clear clarification of it and all business developments and strategies in the forthcoming annual results, rather than a casual vague chat with Alan Kohl, that the vast majority of investors could have so easily missed - including me.
- Forums
- ASX - By Stock
- OCC
- Stem Cell Therapy advancements
Stem Cell Therapy advancements, page-476
Featured News
Add OCC (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.54M |
Open | High | Low | Value | Volume |
37.0¢ | 37.5¢ | 36.5¢ | $15.56K | 42.12K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 119505 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 4986 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 119505 | 0.365 |
12 | 153390 | 0.360 |
6 | 57268 | 0.355 |
7 | 102739 | 0.350 |
2 | 31889 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 4986 | 2 |
0.380 | 29683 | 3 |
0.385 | 45000 | 1 |
0.390 | 21421 | 4 |
0.395 | 30226 | 2 |
Last trade - 13.43pm 20/08/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |